IM Cannabis Corp. (IMCC) shares climbed sharply on Monday, extending gains into Tuesday's premarket session, driven by heavy trading volume despite the absence of any fresh corporate announcements. The stock closed at $0.2610 on June 15, up 12.31% on Nasdaq, and was last seen at $0.3491 in premarket trading at 6:43 a.m. ET on June 16, according to market data from StockAnalysis.
The sudden surge appears to be a classic penny stock move, with Finviz reporting 100.7 million shares traded compared to a 2.30 million average, a volume spike that can propel small-cap stocks when momentum traders pile in. However, such gains can evaporate quickly if buying pressure subsides. Over the past year, IMCC shares are down 89% and trade 93% below their 52-week high.
Dilution Risk Re-emerges
Investor attention is focused on the company's June 9 resale registration filing on Form F-3. If the SEC declares the registration effective, holders of the underlying securities—17,276,931 common shares tied to old convertible notes and warrants—can sell shares in the open market. IM Cannabis will not receive any proceeds from these sales, as noted in the company's press release.
Additionally, on June 3, the company raised US$225,000 through a convertible note, with a conversion price set at the lower of US$0.288 per share or 90% of the lowest daily volume-weighted average price (VWAP), but not lower than US$0.0576. VWAP represents the average price paid per share based on volume over a given period.
Nasdaq Compliance Deadline Looms
IM Cannabis continues to trade below Nasdaq's minimum $1.00 bid price requirement. The company faces an October 6, 2026 deadline to regain compliance by trading at or above that threshold for 10 consecutive business days. Failure to do so could result in delisting, adding further uncertainty for shareholders.
In its SEC filing, the company warned that full conversion of the convertible notes and exercise of the warrants could increase outstanding shares from 9,016,539 to 36,632,436—a 306% jump. This potential dilution could pressure the stock price, as resales or even the fear of resales may weigh on market sentiment.
Financial Performance and Outlook
IM Cannabis reported 2025 revenue of C$54.73 million, primarily from medical cannabis operations in Israel and Germany, under its IMC, BLKMT, and LOT420 brands. However, first-quarter 2026 revenue slipped to C$8.7 million, and the company recorded a net loss of C$2.5 million. The balance sheet is supported by small convertible financings, which could lead to additional share issuance.
Looking ahead, the SEC's decision on the resale registration and the company's progress toward the Nasdaq bid-price deadline are key catalysts. For now, IM Cannabis remains a speculative play with significant dilution risk, ongoing losses, and compliance challenges that make it unattractive from a fundamental perspective.
